Complication of device insertion of dexamethasone intravitreal implant
applicator OzurdexTM malfunction
DOI:
https://doi.org/10.70313/2718.7446.v16.n04.269Keywords:
Ozurdex™, intravitreal dexamethason, cystoid macular edema, retina, complicationsAbstract
Purpose: To report a non-pharmacological complication occurred with the applicator of the dexamethasone intravitreal implant.
Case report: Report a case of a 76-year-old pseudophakic women treated with dexamethasone intravitreal implant (Ozurdex™, Abbvie) because of cystoid macular edema in the left eye. During the procedure a malfunction related to the mandrel during the injection procedure occurred. The mandrel of the device came out of the pen, becoming embedded in the sclera. As soon as the bar was visualized in the sclera, it was removed with the help of Adson forceps. No complications occurred in the retina.
Conclusion: The mandrel of the device could be more damaging than the micronized dexamethasone rod and can be propelled out with sufficient force and speed if it impacts on the contralateral retina. This can occur —as it did in this case— because the mandrel is attached by a plastic portion of only 0.1 mm to the rest of the piece.
Downloads
References
Bernards DA, Ma CJ, Zhang Y et al. Injectable devices for delivery of liquid or solid protein formulations. ACS Materials Au 2023; 3: 255-264.
Meyer CH, Liu Z, German Retinal Vein Occlusion Group et al. Penetration force, geometry, and cutting profile of the novel and old Ozurdex needle: the MONO Study. J Ocul Pharmacol Ther 2014; 30: 387-391.
Iovino C, Mastropasqua R, Lupidi M et al. Intravitreal dexamethasone implant as a sustained release drug delivery device for the treatment of ocular diseases: a comprehensive review of the literature. Pharmaceutics 2020; 12: 703.
Hernanz I, Moll-Udina A, Dotti-Boada M et al. Non-pharmacological complications associated with intravitreal dexamethasone implant injection. Arch Soc Esp Oftalmol (Engl Ed) 2020; 95: 471-477.
Meyer CH, Klein A, Alten F et al. Release and velocity of micronized dexamethasone implants with an intravitreal drug delivery system: kinematic analysis with a high-speed camera. Retina 2012; 32: 2133-2140.
Khurana RN, Appa SN, McCannel CA et al. Dexamethasone implant anterior chamber migration: risk factors, complications, and management strategies. Ophthalmology 2014; 121: 67-71.
Haller JA, Bandello F, Ozurdex Geneva Study Group et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010; 117: 1134.e3-1146.e3.
Christensen L, Sanders R, Olson J. “Magic bullet”: eccentric macular hole as a complication from dexamethasone implant insertion. Case Rep Ophthalmol Med 2016; 2016: 1706234
Panjaphongse R, Liu W, Pongsachareonnont P, Stewart JM. Kinematic study of Ozurdex injection in balanced salt solution: modeling the behavior of an injectable drug delivery device in vitrectomized eyes. J Ocul Pharmacol Ther 2015; 31: 174-178.
Ernst BJ, Velez-Montoya R, Kujundzic D et al. Experimental measure of retinal impact force resulting from intraocular foreign body dropped onto retina through media of differing viscosity: Intraocular foreign body’s impact force. Clin Exp Ophthalmol 2013; 41: 471-475.
Published
Issue
Section
License
Copyright (c) 2023 Consejo Argentino de Oftalmología
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Con esta licencia no se permite un uso comercial de la obra original, ni la generación de obras derivadas. Las licencias Creative Commons permiten a los autores compartir y liberar sus obras en forma legal y segura.
